相关实验视频

Updated: Sep 11, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

基于生物信息学的LMO4-调节的河马途径的探索,以逆转乳腺癌中阿德里亚米辛耐药性的研究

Yue Wu^1,2, Jiahui Gao¹, Zejie Su³

¹Department of Clinical Laboratory, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China.

|August 11, 2025

概括

这项研究表明,LIM域只有4 (LMO4) 蛋白和Hippo信号通路是乳腺癌中获得的阿德里亚米辛耐药性的关键驱动因素. 准LMO4可能有助于逆转化疗耐药性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
细胞信号传递细胞信号传递

背景情况:

在乳腺癌 (BC) 中获得的耐药性降低了治疗有效性和患者的存活率.
在BC中驱动获得的阿德里亚米辛 (ADR) 耐药性的分子机制尚未完全理解.

研究的目的:

研究Hippo信号通路和LIM域只有4 (LMO4) 在抗ADR乳腺癌细胞中的作用.
探索LMO4作为克服化学抵抗的潜在治疗点.

主要方法:

使用了生物信息学和实验方法.
RNA测序 (RNA-seq) 和ATAC测序 (ATAC-seq) 分析了基因表达和染色体的可访问性.
小干扰RNA (siRNA) 用于击败LMO4,并使用Lats激酶抑制剂来调节Hippo路径.

主要成果:

抗ADR的MCF-7细胞显示出缺陷的亡和失调的Hippo通路组件.
通过改变apoptotic蛋白质表达,LMO4敲击部分恢复了ADR敏感性.
LMO4调节Hippo路径,影响YAP核转位和MST1/2酸化.

结论:

LMO4-Hippo信号轴在乳腺癌中关键参与ADR耐药性.
LMO4代表了一个潜在的治疗目标,用于逆转BC的化学抵抗.
这项研究提供了对抗药性机制的见解,并为未来的乳腺癌治疗策略提供了信息.

关键词:

LMO4 LMO4 LMO4 在线播放抗阿德里亚米辛 (ADR) 的抗药性灭症 (apoptosis) 是一种死亡的过程.乳腺癌 (BC) 是一种癌症.药物敏感性药物敏感性河马的信号通道

更多相关视频

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...